As a world-leading multinational pharmaceutical company in the prescription market, AstraZeneca has its headquarters in the UK and its research and development center based in Sweden. It has over 65,000 employees working in manufacturing, sales, clinical research and new product development among over 100 countries and areas. Boasting strong research and development capacities, AstraZeneca invests more than $5 billion in R&D sector every year.
Famously known as the largest multinational pharmaceutical company in the prescription market in China, AstraZeneca China established its headquarters in Shanghai, with 23 branch offices in major cities across China mainland, as well as one office in Hong Kong Special Administrative Region. It has over 3500 employees working in manufacturing, sales, clinical research and new product development. AstraZeneca is committed to being "In China, For China. In China, For Global" with long-term planning and investment. In May 2006, AstraZeneca announced that it would invest $100 million to establish its R&D base, the AstraZeneca Innovation Center China (ICC) in Shanghai. ICC puts its focus on Translational Science. Partnering with major domestic hospitals and medical research institutes, ICC aims to fully support the development of China’s indigenous innovation. ICC’s initial therapeutic area is cancer.
AstraZeneca installed our trusted RotaSec BD turnstiles for its laboratories areas. RotaSec BD is designed to provide bothway passage, which ensures high flow speed, making it an ideal equipment for entrance control and safeguard.
